Real-life medium term follow-up data for intravitreal dexamethasone implant in retinal vein occlusion
Abstract Macular edema (ME) is the most frequent vision threatening consequence after retinal vein occlusion (RVO). In this study, we evaluate the effect of dexamethasone intravitreal implants (DII, Ozurdex) in a real-life cohort of 99 patients with ME due to RVO. All patients who received DII for M...
Guardado en:
Autores principales: | Thomas Wecker, Bastian Grundel, Milena Grundel, Marie-Christine Bründer, Simon Trick, Clemens Lange, Daniel Böhringer, Hansjürgen Agostini, Andreas Stahl |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Nature Portfolio
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/a618870fd8174289bae2b33e07f100e2 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Dexamethasone implant in retinal vein occlusions
por: Han SB, et al.
Publicado: (2016) -
Critical appraisal of the clinical utility of the dexamethasone intravitreal implant (Ozurdex®) for the treatment of macular edema related to branch retinal vein occlusion or central retinal vein occlusion
por: Chan A, et al.
Publicado: (2011) -
Post-marketing surveillance study of the safety of dexamethasone intravitreal implant in patients with retinal vein occlusion or noninfectious posterior segment uveitis
por: Tufail A, et al.
Publicado: (2018) -
Intravitreal bevacizumab injections versus dexamethasone implant for treatment-naïve retinal vein occlusion related macular edema
por: Laine I, et al.
Publicado: (2017) -
Therapeutic effect of dexamethasone implant in retinal vein occlusions resistant to anti-VEGF therapy
por: Wallsh J, et al.
Publicado: (2016)